MENLO PARK, Calif. (AP) — Intersect ENT Inc. (XENT) on Thursday reported a loss of $11.4 million in its second quarter.

The Menlo Park, California-based company said it had a loss of 36 cents per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.

The maker of absorbable nasal implants posted revenue of $26.7 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $27 million.

Intersect ENT expects full-year revenue of $108.5 million.

Intersect ENT shares have decreased 29% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $20.13, a drop of 23% in the last 12 months.

—————

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XENT at https://www.zacks.com/ap/XENT

Automated Insights

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for reading the Daily Journal.

Please purchase an Enhanced Subscription to continue reading.Please log in, or sign up for a new account and purchase an Enhanced Subscription to continue reading.